The way prescription drugs are priced in the U.S. is changing fast — and the companies at the centre of that change could be worth paying close attention to. Getting in early on a structural industry shift is exactly the kind of opportunity long-term investors look for.
Major pharmaceutical companies are pledging enormous capital investments into domestic manufacturing — and the logistics and supply chain firms supporting that build-out could see serious tailwinds. This is industrial-scale momentum that analysts are actively tracking.
As patients search for cheaper, more accessible medications, digital health platforms and prescription savings apps are seeing surging demand. Companies like GoodRx, Hims & Hers, and Teladoc sit right at the intersection of tech and healthcare — a space that experts believe is only going to grow.
This basket's total market capitalisation is $1.34T and is heavily anchored by large-cap pharmaceutical and healthcare holdings.
GSK: $110.19B
AZN: $291.14B
BMY: $120.31B
The TrumpRx platform is reshaping how prescription drugs are priced and distributed across the United States. As pharmaceutical giants like GSK and Amgen commit to most-favoured-nation pricing and pour billions into domestic manufacturing, a ripple effect is spreading across logistics, supply chains, and digital health. This group captures that ripple — from drug makers to the companies moving and connecting those medicines to patients.
This is a thematic basket, meaning it groups companies that are all connected to the same big trend rather than a single industry. It spans global pharma developers, specialist logistics providers, and consumer-facing digital health platforms. Because it covers multiple sectors, it offers a broad lens on the shifting healthcare landscape — but as with any investment, the value of these stocks can go up as well as down.
Each stock in this group was handpicked by professional analysts to reflect a different piece of the TrumpRx story. Pharmaceutical companies are named participants or stand-out beneficiaries of domestic production incentives. Logistics firms are critical to moving medicines safely and efficiently. And digital health platforms are front and centre as patients navigate new ways to access and afford their prescriptions.
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
Published on March 14
+5
Get the full story on this Basket. Read our detailed article on its risks and potential.
Read Full Insight
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Here are a few of the assets in this group. Create an account to unlock the full list.
ASTRAZENECA PLC
AZN
Current Price
$156.37
A major biopharmaceutical player that could integrate its extensive pipeline with new digital health aggregators to navigate revised pricing structure...
A major biopharmaceutical player that could integrate its extensive pipeline with new digital health aggregators to navigate revised pricing structures.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
On average, analysts expect assets in this group to grow 11.64% over the next year.
10 of 15 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+11.64%
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
